Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule ligand-fluorescent dye conjugates - On Target Laboratories

Next Previous
Drug Profile

Research programme: small molecule ligand-fluorescent dye conjugates - On Target Laboratories

Alternative Names: OTL 228; OTL 338; OTL 489; OTL 578; OTL 81

Latest Information Update: 28 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endocyte; Purdue University
  • Developer On Target Laboratories
  • Class Diagnostic conjugates; Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Nov 2022 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA (Parenteral)
  • 21 Dec 2018 Endocyte has been acquired by Novartis
  • 15 Oct 2018 On Target Laboratories receives SBIR grant from the National Institutes of Health (NIH) for development of OTL 338 and OTL 489 programmes in Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top